or nebulization (7%), or ipratropium bromide in a fixed-dose combination with albuterol (38%). Overall, exposure to anticholinergics was associated with a 29% higher risk of CVEs relative to no ...
Ipratropium (brand name, Atrovent HFA; Boehringer-Ingelheim) is a short-acting bronchodilator. It is used to prevent wheezing, shortness of breath, coughing, and chest tightness in people with COPD.
Several single-dose studies comparing acute bronchodilation induced by ipratropium bromide with salbutamol have shown that salbutamol was more effective than ipratropium in asthma treatment.
Bronchodilators to open the airways (e.g., albuterol or ipratropium bromide and albuterol) Untreated anaphylaxis can lead to hypotension (low blood pressure), incontinence, fainting, shock ...